Basilea Pharmaceutica (BSLN) is a Swiss biopharmaceutical company, founded in 2000 and located in Basel, Switzerland. The company discovers, develops and commercialises innovative pharmaceutical products for fungal and bacterial infections, as well as cancer. Basilea Pharmaceutica owns such brands as Zevtera/Mabelio, Cresemba and Toctino. Since 2004, Basilea Pharmaceutica has been listed on the SIX Swiss Exchange. Follow the Basilea Pharma share price (BSLN) at Capital.com.
Latest shares articles
Market Analysis: US stocks under pressure ahead of US PCE data
US stocks attempt to recover despite Trump announcing 25% tariffs on auto imports, US PCE in focus
12:36, 27 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
10:12, 11 March 2025
Nvidia shares dive as trade war fears drive tech correction
Nvidia shares plunge 30% from record highs amid trade war concerns, weakening market sentiment, and investor rotation into European and Asian stocks. Learn more about the factors driving the downturn.
11:21, 10 March 2025
Lithium Americas forecast: Third-party price target
Discover the Lithium Americas (LAC) price predictions for 2025 and beyond, with analyst price targets and more on Capital.com
12:04, 3 March 2025